Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. [electronic resource]
Producer: 20120208Description: 1199-206 p. digitalISSN:- 1461-7285
- Administration, Inhalation
- Adult
- Anti-Anxiety Agents -- adverse effects
- Anxiety -- chemically induced
- Carbon Dioxide -- administration & dosage
- Double-Blind Method
- Female
- Human Experimentation
- Humans
- Lorazepam -- pharmacology
- Male
- Receptors, Corticotropin-Releasing Hormone -- antagonists & inhibitors
- Surveys and Questionnaires
- Young Adult
- CRF Receptor, Type 1
No physical items for this record
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.